Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease

Abstract

Recent pharmaceutical trials have demonstrated that slowing or reversing pathology in Alzheimer's disease is likely to be possible only in the earliest stages of disease, perhaps even before significant symptoms develop. Pathology in Alzheimer's disease accumulates for well over a decade before symptoms are detected giving a large potential window of opportunity for intervention. It is therefore important that imaging techniques detect subtle changes in brain tissue before significant macroscopic brain atrophy. Current diagnostic techniques often do not permit early diagnosis or are too expensive for routine clinical use. Magnetic Resonance Imaging (MRI) is the most versatile, affordable, and powerful imaging modality currently available, being able to deliver detailed analyses of anatomy, tissue volumes, and tissue state. In this mini-review, we consider how MRI might detect patients at risk of future dementia in the early stages of pathological change when symptoms are mild. We consider the contributions made by the various modalities of MRI (structural, diffusion, perfusion, relaxometry) in identifying not just atrophy (a late-stage AD symptom) but more subtle changes reflective of early dementia pathology. The sensitivity of MRI not just to gross anatomy but to the underlying “health” at the cellular (and even molecular) scales, makes it very well suited to this task.

Magnetic Nanoparticles Applications for Amyloidosis Study and Detection: A Review

“…AGuIX nanoparticles have a hydrodynamic diameter smaller than 5 nm and have been already efficiently used for MRI imaging and radio-sensitization [ 110 ]. Free ligands are available at the surface of AGuIX and can be used to chelate radioisotopes (e.g., 68 Ga 3+ or 111 In 3+ ) in order to perform PET or Single-photon emission computed tomography (SPECT) imaging [ 111 , 112 ]. Moreover, the covalent grafting of a near-infrared dye, such as cyanine5.5 (Cy5.5), is also achievable for optical imaging [ 113 ].…”

Combining Structural Magnetic Resonance Imaging and Visuospatial Tests to Classify Mild Cognitive Impairment

“…Recent pharmaceutical trials have demonstrated that slowing or reversing pathology in Alzheimer's disease (AD) is likely to be possible only in the earliest stages of disease, perhaps even before significant symptoms develop [1]. The development and use of diagnostic tools for the early detection of AD, therefore, might be helpful for clinicians.…”

A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults

“…Imaging biomarkers of neurodegeneration include [ 18 F]fluorodeoxyglucose positron emission tomography ([ 18 F]FDG-PET) 1 , 2 and magnetic resonance imaging (MRI) hippocampal volume measures. 3 Although both of these biomarkers are nonspecific to Alzheimer’s disease (AD), they can provide evidence about its severity due to neuronal damages. It is known that pathological phenomena that lead to synaptic dysfunction affect metabolism before cell death and detectable atrophy.…”